New antibody could block malaria transmission in High-Risk areas
NCT ID NCT06413108
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a monoclonal antibody called TB31F in 167 adults and children in Mali who are regularly exposed to malaria. The goal was to see if the antibody is safe and can reduce the spread of the malaria parasite from humans to mosquitoes. Participants received either the antibody or a placebo, and researchers measured side effects and how well the antibody worked in blood samples. This is an early-stage trial focused on safety and transmission reduction, not a cure for malaria.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA, FALCIPARUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Faculty of Pharmacy and Faculty of Medicine and Dentistry, University of Sciences Techniques and Technologies of Bamako
Bamako, Point G, BP1805, Mali
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental malaria vaccine aims to block parasite growth
- New malaria drug interaction study launches in healthy volunteers
- New malaria shots could replace daily pills
- New malaria antibody enters first human safety tests
- Breastfeeding moms with malaria: do drugs reach baby?
- New malaria pill shows promise in early trial